Celltrion and Teva announce U.S. FDA acceptance of biologics license application for proposed biosimilar to herceptin® (trastuzumab)
admin 1st August 2017 Uncategorised 0Teva Pharmaceutical Industries
More: Celltrion and Teva announce U.S. FDA acceptance of biologics license application for proposed biosimilar to herceptin® (trastuzumab)
Source: MDlinx